阿替利珠单抗联合贝伐珠单抗——肝癌治疗的里程碑
Atezolizumab plus Bevacizumab — A Landmark in Liver Cancer
N Engl J Med 2020;382:1953-5
Robin K. Kelley
参考文献
1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
2. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.
3. Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012;17:1063-72.
4. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-8.
5. Thomas MB, Garrett-Mayer E, Anis M, et al. A randomized phase II open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the firstline treatment of patients with advanced hepatocellular carcinoma. Oncology 2018;94:329-39.
6. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15.
7. Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Presented at the 2019 Congress of the European Society of Medical Oncology, Barcelona, September 27–October 1, 2019. abstract.
8. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
9. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as secondline therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202.
10. Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 2017;153:812-26.
11. Lee M, Ryoo B-Y, Hsu C, et al. Randomised efficacy and safety results for atezolizumab (ATEZO) + bevacizumab (BEV) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Presented at the 2019 Congress of the European Society of Medical Oncology, Barcelona, September 27– October 1, 2019. abstract.
12. Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res 2019;25:5449-57.
13. Food and Drug Administration. FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. March 10, 2020 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma).
联系客服